PharmAla Biotech said in April that it still expected ALA-002, its patented MDMA-derived drug candidate, to be dosed in patients in 2026, and in July that GMP manufacturing of the drug substance was complete. The finished drug product is still in development: on November 5 the company announced that Corealis Pharma, a contract manufacturer in Laval, Québec, had begun formulation work. The release gave no timing beyond scheduling the first batch “upon completion of development activities.”
Asked the same day when it expected the first GMP drug-product batch and first dosing, PharmAla chief executive Nick Kadysh answered:
“PharmAla expects GMP drug product to be released at earliest in December and at latest in February. Unfortunately this means that it is unlikely that any patients will be dosed in calendar 2026.”
— Nick Kadysh, chief executive of PharmAla Biotech, in comments to Behavioral Wire
Nothing in the public record suggests the program has been cancelled or that a study has failed. What has moved is the date. Kadysh ties the new timing to the release of the finished drug product, and neither he nor the release says what set the December-to-February window.
The ingredient was made. The finished dose was not.
A drug reaches a patient in two manufacturing stages. The drug substance is the active ingredient. The drug product is the finished dose: the ingredient formulated with other components into a dosage form such as a capsule, made under good manufacturing practice (GMP) and tested before release. Only the second can be given to a trial participant.
PharmAla’s public record shows the two stages moving at different speeds:
| Date | What PharmAla said |
|---|---|
| December 2025 | Its Australian subsidiary contracted an unnamed UK manufacturer for ALA-002 drug substance. PharmAla said it would begin Phase 2a/2b research in social anxiety disorder in 2026. |
| April 20, 2026 | GMP manufacturing of the active ingredient had started. “Consistent with prior guidance,” it still expected ALA-002 to be dosed in patients in 2026. |
| July 6, 2026 | Completed GMP manufacturing of drug substance “necessary for the manufacturing of ALA-002,” and was “prepared to begin” GMP manufacturing of the drug product. |
| November 5, 2026 | Corealis signed as drug-product manufacturer, with formulation research and development under way. |
Four months passed between PharmAla’s July 6 statement that it was prepared to begin drug-product manufacturing and the November 5 announcement of a manufacturer. Neither the release nor Kadysh’s answers to Behavioral Wire say why, or attribute the timing to Corealis. The release does show where the program now waits: it quotes Kadysh calling a completed GMP drug-product formulation “a necessary step for clinical research.”
Even a February release is a step short of a patient. After a batch is released, a trial still needs clinical sites ready, authorization from the relevant regulator and ethics approval before anyone is dosed. Kadysh did not say when dosing would begin or whether the Phase 2a/2b social anxiety study PharmAla announced for 2026 is still the next study, and the company has not said where it would run. Searches of ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry on November 6 found no registered ALA-002 study, which says nothing about one planned but unregistered. Kadysh said PharmAla will endeavor to update the market once release is certain.
What ALA-002 is, and the 50 mg dose
Conventional MDMA is an equal mixture of two mirror-image forms, called R and S. ALA-002 is what PharmAla’s license with Jupiter Neurosciences defines as a “non-racemic mixture of MDMA enantiomers”: both forms, in unequal proportions that the filed agreement redacts.
PharmAla holds a U.S. patent on such mixtures and says the composition was designed to reduce MDMA’s cardiovascular effects.
The November 5 release also named a dose strength, which the July license had redacted: ALA-002 “will initially be developed and launched as a 50mg capsule.” PharmAla also sells 40 mg LaNeo MDMA capsules for authorized prescribing and research. Asked about the 50 mg capsule and the existing LaNeo capsules, Kadysh answered:
“The 50mg will be the standard dosage for ALA-002. … these are different drug products with different active ingredients.”
— Nick Kadysh, chief executive of PharmAla Biotech, in comments to Behavioral Wire
He did not say whether the Corealis capsule is the formulation for the next clinical study. A standard dose is a development and manufacturing choice, not a dose any regulator has approved. PharmAla describes LaNeo as clinical-grade MDMA.
Two programs, two routes to finished doses
ALA-002 now runs on two tracks. Under a Strategic Asset License Agreement signed July 20 and filed with the SEC by Jupiter, Jupiter holds exclusive U.S. rights and must develop the drug at its own cost. PharmAla keeps all rights outside the United States.
Asked who the Corealis material is for and whether a Jupiter supply agreement is final, Kadysh answered:
“The Corealis material will be made available to Jupiter, although they do have the ability to manufacture their own supply in the US should they choose to. The License agreement contemplates a price, so a supply agreement is just the decision by Jupiter as to how much they want. At this time they have not made that election. The material will be used in PharmAla’s ex-US program.”
— Nick Kadysh, chief executive of PharmAla Biotech, in comments to Behavioral Wire
The filed license adds steps:
- Jupiter has “sole and exclusive responsibility” for manufacturing ALA-002 for U.S. use, at its own cost.
- At Jupiter’s request, PharmAla is to arrange supply of GMP drug substance or drug product under a separate supply agreement to be negotiated in good faith. The license caps the unit price, though the figure is redacted.
- No supply obligation arises until the companies sign that supply agreement and a quality agreement.
No filing discloses a supply agreement. Jupiter’s filings describe the license but disclose no ALA-002 trial plan, manufacturer or timetable.
The contract also shows why finished doses matter to Jupiter whichever route it chooses. Its Schedule D deadlines run from finished product, not from the active ingredient: an investigational new drug application (IND) to the FDA is due within three months after “establishment of finished dose ALA-002 product inventory plus 3 months stability,” and a Phase 1 protocol within six months of the same point. The license calls these deadlines “a binding diligence framework”: if Jupiter misses one and does not cure within 90 days of notice, PharmAla may terminate, with extensions for causes that include regulator action and PharmAla’s own failure to perform. The agreement does not say when inventory is established or whose inventory counts.
If PharmAla’s finished product were that inventory and its release window held, the IND deadline would fall between about June and August 2027: release, plus three months of stability, plus the three-month filing window (Behavioral Wire’s arithmetic). That is a conditional calculation from the contract, not a filing date Jupiter has announced.
What the money depends on
PharmAla’s July 21 release put the license’s total consideration at “up to approximately US$100 million.” Only the $3.33 million upfront payment, in cash and Jupiter shares, does not depend on development or sales. The next, $3.33 million, waits for first dosing in a U.S. Phase 3 trial; $20 million follows FDA approval, and $73.3 million depends on U.S. net sales reaching $333 million, $1 billion and $2 billion. Every contingent payment sits several trials beyond the first released batch.
The Corealis agreement is a contract to develop and make the first finished doses of ALA-002, not a released batch. By PharmAla’s account its drug substance has been complete since July; its timeline now depends on how quickly released finished doses follow.